NASDAQ:CORT

Corcept Therapeutics (CORT) Stock Price, News & Analysis

$28.09
+0.55 (+2.00%)
(As of 05/17/2024 ET)
Today's Range
$27.53
$28.31
50-Day Range
$22.21
$28.09
52-Week Range
$20.84
$34.28
Volume
823,758 shs
Average Volume
1.44 million shs
Market Capitalization
$2.92 billion
P/E Ratio
26.50
Dividend Yield
N/A
Price Target
$40.10

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
42.8% Upside
$40.10 Price Target
Short Interest
Bearish
22.07% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
0.74mentions of Corcept Therapeutics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$3.21 M Sold Last Quarter
Proj. Earnings Growth
44.33%
From $0.97 to $1.40 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.94 out of 5 stars

Medical Sector

26th out of 922 stocks

Pharmaceutical Preparations Industry

9th out of 427 stocks

CORT stock logo

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

CORT Stock News Headlines

Corcept: Q1 Earnings Snapshot
Corcept Completes Enrollment in Phase 4 CATALYST Trial
Corcept Therapeutics Incorporated (CORT)
3 Promising Biotech Stocks Driving Weekly Gains
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/01/2024
Today
5/17/2024
Next Earnings (Estimated)
8/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
352
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$40.10
High Stock Price Target
$47.50
Low Stock Price Target
$31.00
Potential Upside/Downside
+42.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$106.14 million
Pretax Margin
26.95%

Debt

Sales & Book Value

Annual Sales
$482.38 million
Cash Flow
$0.97 per share
Book Value
$5.26 per share

Miscellaneous

Free Float
82,767,000
Market Cap
$2.92 billion
Optionable
Optionable
Beta
0.50

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price target for 2024?

4 equities research analysts have issued twelve-month price objectives for Corcept Therapeutics' stock. Their CORT share price targets range from $31.00 to $47.50. On average, they anticipate the company's stock price to reach $40.10 in the next year. This suggests a possible upside of 42.8% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2024?

Corcept Therapeutics' stock was trading at $32.48 on January 1st, 2024. Since then, CORT stock has decreased by 13.5% and is now trading at $28.09.
View the best growth stocks for 2024 here
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.21 by $0.04. The biotechnology company earned $146.80 million during the quarter, compared to the consensus estimate of $141.19 million. Corcept Therapeutics had a net margin of 22.38% and a trailing twelve-month return on equity of 24.19%. Corcept Therapeutics's revenue was up 38.9% compared to the same quarter last year. During the same period last year, the business posted $0.14 EPS.

What guidance has Corcept Therapeutics issued on next quarter's earnings?

Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Wednesday, May, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $620.0 million-$650.0 million, compared to the consensus revenue estimate of $610.6 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.19%), Norden Group LLC (1.92%), Ikarian Capital LLC (0.00%), Jupiter Asset Management Ltd. (0.72%), Jacobs Levy Equity Management Inc. (0.70%) and Kynam Capital Management LP (0.00%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 5/17/2024 by MarketBeat.com Staff

From Our Partners